{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:05:59Z","timestamp":1781100359640,"version":"3.54.1"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project DEAL"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycoplasma pneumoniae is a common cause of human respiratory infections. Extrapulmonary manifestations include diseases of the central nervous system (CNS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To summarize the current knowledge on M. pneumoniae\u2013associated CNS complications, cases published in PubMed between 2015 and 2025 were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 70 studies with 207 patients. Various neurological manifestations were identified, affecting patients between the ages of 3 and 69. Cases of encephalitis predominated (72%). Diagnosis of M. pneumoniae involvement was confirmed primarily by the detection of specific antibodies in serum. The prodromal phase between respiratory and neurological symptoms (&amp;lt;7 vs \u2265 7 days) was distributed almost evenly. In most cases, antibiotics effective against mycoplasma are used (88%), and in 81% of patients, complete recovery was achieved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the administration of antibiotics is accepted for the treatment of CNS manifestations, the use of other therapies is guided by the severity of the course and empirical considerations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag333","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:23:48Z","timestamp":1780313028000},"source":"Crossref","is-referenced-by-count":0,"title":["<i>Mycoplasma pneumoniae<\/i>\n                    \u2013associated Central Nervous System Manifestations: Current Knowledge and Challenges"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-0717","authenticated-orcid":false,"given":"Oluwafemi M","family":"Akinnurun","sequence":"first","affiliation":[{"name":"TU Dresden, Institute of Medical Microbiology and Virology , Dresden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-8817","authenticated-orcid":false,"given":"Roger","family":"Dumke","sequence":"additional","affiliation":[{"name":"TU Dresden, Institute of Medical Microbiology and Virology , Dresden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026061009403905500_ofag333-B1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond","volume":"30","author":"Waites","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2026061009403905500_ofag333-B2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/INF.0000000000000171","article-title":"Mycoplasma pneumoniae infections in childhood","volume":"33","author":"Atkinson","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2026061009403905500_ofag333-B3","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2666-5247(22)00190-2","article-title":"Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?","volume":"3","author":"Meyer Sauteur","year":"2022","journal-title":"Lancet Microbe"},{"key":"2026061009403905500_ofag333-B4","doi-asserted-by":"crossref","first-page":"101019","DOI":"10.1016\/j.lanmic.2024.101019","article-title":"Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study","volume":"6","author":"ESGMAC MAPS Study Group","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026061009403905500_ofag333-B5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/QCO.0000000000001126","article-title":"Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities","volume":"38","author":"de Groot","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"2026061009403905500_ofag333-B6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jiac.2013.09.009","article-title":"Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature","volume":"20","author":"Izumikawa","year":"2014","journal-title":"J Infect Chemother"},{"key":"2026061009403905500_ofag333-B7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. children","volume":"372","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"2026061009403905500_ofag333-B8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.cmi.2016.05.028","article-title":"Increased rates of intensive care unit admission in patients with Mycoplasma pneumoniae: a retrospective study","volume":"22","author":"Khoury","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2026061009403905500_ofag333-B9","article-title":"Prevalence of atypical pathogens in patients with severe pneumonia: a systematic review and meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"2026061009403905500_ofag333-B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fmicb.2016.00023","article-title":"Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis","volume":"7","author":"Narita","year":"2016","journal-title":"Front Microbiol"},{"key":"2026061009403905500_ofag333-B11","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3389\/fmicb.2018.02751","article-title":"Pathogenesis and treatment of neurologic diseases associated with Mycoplasma pneumoniae infection","volume":"9","author":"D'Alonzo","year":"2018","journal-title":"Front Microbiol"},{"key":"2026061009403905500_ofag333-B12","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S0163-4453(17)30198-6","article-title":"Things that could be Mycoplasma pneumoniae","volume":"74 Suppl 1","author":"de Groot","year":"2017","journal-title":"J Infect"},{"key":"2026061009403905500_ofag333-B13","doi-asserted-by":"crossref","first-page":"101103","DOI":"10.1016\/j.lanepe.2024.101103","article-title":"Mycoplasma pneumoniae incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a nationwide multicentre population-based cohort study","volume":"47","author":"Dungu","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026061009403905500_ofag333-B14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00431-025-06326-y","article-title":"Evolving clinical features of Mycoplasma pneumoniae infections following COVID-19 pandemic restrictions: a retrospective, comparative cohort study","volume":"184","author":"Robinson","year":"2025","journal-title":"Eur J Pediatr"},{"key":"2026061009403905500_ofag333-B15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fneur.2018.01109","article-title":"Stroke associated with recent Mycoplasma pneumoniae infection: a systematic review of clinical features and presumed pathophysiological mechanisms","volume":"9","author":"Mele","year":"2018","journal-title":"Front Neurol"},{"key":"2026061009403905500_ofag333-B16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s10072-017-2922-9","article-title":"Isolated optic neuritis associated with Mycoplasma pneumoniae infection: report of two cases and literature review","volume":"38","author":"Choi","year":"2017","journal-title":"Neurol Sci"},{"key":"2026061009403905500_ofag333-B17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1186\/s12879-016-1985-1","article-title":"Mycoplasma pneumoniae-associated mild encephalitis\/encephalopathy with a reversible splenial lesion: report of two pediatric cases and a comprehensive literature review","volume":"16","author":"Ueda","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026061009403905500_ofag333-B18","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1093\/clinids\/17.Supplement_1.S52","article-title":"CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review","volume":"17","author":"Koskiniemi","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2026061009403905500_ofag333-B19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pediatrneurol.2009.04.012","article-title":"Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection","volume":"41","author":"Narita","year":"2009","journal-title":"Pediatr Neurol"},{"key":"2026061009403905500_ofag333-B20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archinte.1956.00250190109010","article-title":"Central nervous system complications of primary atypical pneumonia","volume":"97","author":"Yesnick","year":"1956","journal-title":"AMA Arch Intern Med"},{"key":"2026061009403905500_ofag333-B21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/INF.0000000000004461","article-title":"Increased severity of Mycoplasma pneumoniae infections in Spanish children","volume":"43","author":"Mendez-Echevarria","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"2026061009403905500_ofag333-B22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/01658107.2016.1237975","article-title":"A rare case of bilateral optic neuritis and Guillain-Barr\u00e9 syndrome post Mycoplasma pneumoniae infection","volume":"41","author":"Baheerathan","year":"2016","journal-title":"Neuroophthalmology"},{"key":"2026061009403905500_ofag333-B23","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1097\/INF.0000000000004946","article-title":"Mycoplasma pneumoniae: extrapulmonary manifestations in children with focus on mucocutaneous disease","volume":"44","author":"Meyer Sauteur","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"2026061009403905500_ofag333-B24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3988\/jcn.2022.0328","article-title":"Determining the clinical characteristics, treatment strategies, and prognostic factors for Mycoplasma pneumoniae encephalitis in children: a multicenter study in China","volume":"19","author":"Fan","year":"2023","journal-title":"J Clin Neurol"},{"key":"2026061009403905500_ofag333-B25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1017\/S0950268810000725","article-title":"Causality in acute encephalitis: defining aetiologies","volume":"138","author":"Granerod","year":"2010","journal-title":"Epidemiol Infect"},{"key":"2026061009403905500_ofag333-B26","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1086\/320748","article-title":"Acute childhood encephalitis and Mycoplasma pneumoniae","volume":"32","author":"Bitnun","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026061009403905500_ofag333-B27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/08830738040190110401","article-title":"Diagnosis, treatment, and prognosis of Mycoplasma pneumoniae childhood encephalitis: systematic review of 58 cases","volume":"19","author":"Daxboeck","year":"2004","journal-title":"J Child Neurol"},{"key":"2026061009403905500_ofag333-B28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jinf.2005.07.005","article-title":"Central nervous system manifestations of Mycoplasma pneumoniae infections","volume":"51","author":"Tsiodras","year":"2005","journal-title":"J Infect"},{"key":"2026061009403905500_ofag333-B29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11908-010-0105-4","article-title":"Mycoplasma pneumoniae: innocent bystander or a true cause of central nervous system disease?","volume":"12","author":"Bitnun","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"2026061009403905500_ofag333-B30","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1542\/peds.2014-2702","article-title":"Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome","volume":"135","author":"Pillai","year":"2015","journal-title":"Pediatrics"},{"key":"2026061009403905500_ofag333-B31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1542\/peds.2007-0240","article-title":"Pediatric encephalitis: what is the role of Mycoplasma pneumoniae?","volume":"120","author":"Christie","year":"2007","journal-title":"Pediatrics"},{"key":"2026061009403905500_ofag333-B32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1473-3099(24)00805-3","article-title":"Mycoplasma pneumoniae infection in adult inpatients during the 2023\u201324 outbreak in France (MYCADO): a national, retrospective, observational study","volume":"25","author":"Gavaud","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026061009403905500_ofag333-B33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pediatrneurol.2005.03.003","article-title":"Cytokines involved in CNS manifestations caused by Mycoplasma pneumoniae","volume":"33","author":"Narita","year":"2005","journal-title":"Pediatr Neurol"},{"key":"2026061009403905500_ofag333-B34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/cid\/civ473","article-title":"Neurological complications of PCR-proven M. pneumoniae infections in children: prodromal illness duration may reflect pathogenetic mechanism","volume":"61","author":"Al-Zaidy","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026061009403905500_ofag333-B35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.880180407","article-title":"Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection","volume":"18","author":"Kusunoki","year":"1995","journal-title":"Muscle Nerve"},{"key":"2026061009403905500_ofag333-B36","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-234565","article-title":"Seropositive anti-MOG antibody-associated acute disseminated encephalomyelitis (ADEM): a sequelae of Mycoplasma pneumoniae infection","volume":"13","author":"Bonagiri","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2026061009403905500_ofag333-B37","doi-asserted-by":"crossref","first-page":"1393540","DOI":"10.3389\/fmed.2024.1393540","article-title":"Case report: a co-occurring case of severe Mycoplasma pneumoniae pneumonia and anti-IgLON5 antibody-associated encephalitis in a pediatric patient","volume":"11","author":"Ye","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026061009403905500_ofag333-B38","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10096-009-0799-0","article-title":"Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis","volume":"28","author":"Gable","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026061009403905500_ofag333-B39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1017\/cjn.2019.337","article-title":"Anti-GM2 antibodies in Mycoplasma pneumoniae-associated acute encephalomyelitis","volume":"47","author":"Xia","year":"2020","journal-title":"Can J Neurol Sci"},{"key":"2026061009403905500_ofag333-B40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/088307389701200612","article-title":"Bickerstaff's brainstem encephalitis associated with IgG anti-GQ1b antibody subsequent to Mycoplasma pneumoniae infection: favorable response to immunoadsorption therapy","volume":"12","author":"Kikuchi","year":"1997","journal-title":"J Child Neurol"},{"key":"2026061009403905500_ofag333-B41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2017.11.011","article-title":"Intrathecal antibody responses to GalC in Guillain-Barr\u00e9 syndrome triggered by Mycoplasma pneumoniae","volume":"314","author":"Meyer Sauteur","year":"2018","journal-title":"J Neuroimmunol"},{"key":"2026061009403905500_ofag333-B42","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1002\/ccr3.3342","article-title":"Clinically mild encephalitis\/encephalopathy with reversible splenial lesion (MERS) associated with Mycoplasma pneumoniae pneumonia: an adult case and review of the literature","volume":"8","author":"Sadohara","year":"2020","journal-title":"Clin Case Rep"},{"key":"2026061009403905500_ofag333-B43","article-title":"Atypical cause of autoimmune encephalitis: the role of Mycoplasma pneumoniae in status epilepticus","volume":"17","author":"Horton","year":"2025","journal-title":"Cureus"},{"key":"2026061009403905500_ofag333-B44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10096-025-05101-z","article-title":"Clinical characteristics and associated factors of macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis","volume":"44","author":"Yang","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026061009403905500_ofag333-B45","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02908-23","article-title":"SARS-CoV-2 pandemic non-pharmacologic interventions temporally associated with reduced pediatric infections due to Mycoplasma pneumoniae and co-infecting respiratory viruses in Arkansas","volume":"12","author":"Boyanton","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2026061009403905500_ofag333-B46","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1097\/INF.0000000000004734","article-title":"Severe Mycoplasma pneumoniae infections during the 2023\u20132024 outbreak: a single-center descriptive study in a pediatric intensive care","volume":"44","author":"Espeleta-Fox","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"2026061009403905500_ofag333-B47","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01279-25","article-title":"Changing patterns of respiratory pathogens in hospitalized children with community-acquired pneumonia in northern China following the lifting of non-pharmaceutical interventions","volume":"13","author":"Jiang","year":"2025","journal-title":"Microbiol Spectr"},{"key":"2026061009403905500_ofag333-B48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001444","article-title":"Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study","volume":"10","author":"Spuesens","year":"2013","journal-title":"PLoS Med"},{"key":"2026061009403905500_ofag333-B49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10096-018-03448-0","article-title":"Pharmacokinetic considerations in selecting optimal antibiotic therapy for Mycoplasma pneumoniae encephalitis","volume":"38","author":"Cunha","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026061009403905500_ofag333-B50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.14740\/jocmr3421w","article-title":"Mycoplasma pneumoniae: a potentially severe infection","volume":"10","author":"Bajantri","year":"2018","journal-title":"J Clin Med Res"},{"key":"2026061009403905500_ofag333-B51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13052-024-01768-w","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated encephalitis induced by Mycoplasma pneumoniae infections","volume":"50","author":"Liu","year":"2024","journal-title":"Ital J Pediatr"},{"key":"2026061009403905500_ofag333-B52","doi-asserted-by":"crossref","first-page":"116418","DOI":"10.1016\/j.diagmicrobio.2024.116418","article-title":"Current Mycoplasma pneumoniae outbreak: don't forget its role in Bickerstaff encephalitis","volume":"110","author":"Lacampagne","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026061009403905500_ofag333-B53","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s10096-024-04935-3","article-title":"Meningitis and intracranial abscess due to Mycoplasma pneumoniae in a B cell-depleted patient with multiple sclerosis","volume":"43","author":"Madzar","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026061009403905500_ofag333-B54","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1097\/INF.0000000000004394","article-title":"Concomitant central and peripheral nervous system involvement associated with Mycoplasma pneumoniae infection in pediatric patients: two case reports and literature review","volume":"43","author":"Xue","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"2026061009403905500_ofag333-B55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0883073819854854","article-title":"Intravenous immunoglobulin as a therapeutic option for Mycoplasma pneumoniae encephalitis","volume":"34","author":"Daba","year":"2019","journal-title":"J Child Neurol"},{"key":"2026061009403905500_ofag333-B56","first-page":"e29607","article-title":"A rare presentation of a complex mixed autoimmune encephalitis diagnosis: a case report and literature review","volume":"14","author":"Khunkhun","year":"2022","journal-title":"Cureus"},{"key":"2026061009403905500_ofag333-B57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13256-022-03299-6","article-title":"Mild encephalitis\/encephalopathy with a reversible splenial lesion associated with systemic Mycoplasma pneumoniae infection in North America: a case report","volume":"16","author":"Talukder","year":"2022","journal-title":"J Med Case Rep"},{"key":"2026061009403905500_ofag333-B58","doi-asserted-by":"crossref","first-page":"987968","DOI":"10.3389\/fimmu.2022.987968","article-title":"Case report: a pediatric case of Bickerstaff brainstem encephalitis after COVID-19 vaccination and Mycoplasma pneumoniae infection: looking for the culprit","volume":"13","author":"Monte","year":"2022","journal-title":"Front Immunol"},{"key":"2026061009403905500_ofag333-B59","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ped.14524","article-title":"Cerebral infarction associated with Mycoplasma pneumoniae infection in a child","volume":"63","author":"Ding","year":"2021","journal-title":"Pediatr Int"},{"key":"2026061009403905500_ofag333-B60","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/cid\/ciae451","article-title":"Outcomes of adjunctive corticosteroid treatment in hypoxemic adults hospitalized for Mycoplasma pneumoniae pneumonia: a retrospective cohort study","volume":"80","author":"Hagman","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026061009403905500_ofag333-B61","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1007\/s10072-025-08231-6","article-title":"Acute bilateral optic\/chiasm neuritis with longitudinally extensive transverse myelitis and positive anti-ganglioside antibodies following Mycoplasma pneumoniae pneumonia: a case report and literature review","volume":"46","author":"Zhao","year":"2025","journal-title":"Neurol Sci"},{"key":"2026061009403905500_ofag333-B62","doi-asserted-by":"crossref","first-page":"w14222","DOI":"10.4414\/smw.2016.14222","article-title":"Swiss national prospective surveillance of pediatric Mycoplasma pneumoniae-associated encephalitis","volume":"146","author":"Meyer Sauteur","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"2026061009403905500_ofag333-B63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s40064-016-1832-2","article-title":"Mycoplasma-induced minimally conscious state","volume":"5","author":"Horvath","year":"2016","journal-title":"Springerplus"},{"key":"2026061009403905500_ofag333-B64","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00431-008-0714-1","article-title":"Mycoplasma pneumoniae: nervous system complications in childhood and review of the literature","volume":"167","author":"Yis","year":"2008","journal-title":"Eur J Pediatr"},{"key":"2026061009403905500_ofag333-B65","doi-asserted-by":"crossref","first-page":"904494","DOI":"10.3389\/fmicb.2022.904494","article-title":"Molecular tools for typing Mycoplasma pneumoniae and Mycoplasma genitalium","volume":"13","author":"Dumke","year":"2022","journal-title":"Front Microbiol"},{"key":"2026061009403905500_ofag333-B66","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/IAI.00268-09","article-title":"Strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development","volume":"77","author":"Schurwanz","year":"2009","journal-title":"Infect Immun"},{"key":"2026061009403905500_ofag333-B67","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/INF.0000000000001476","article-title":"Epidemiology and molecular characteristics of Mycoplasma pneumoniae during an outbreak of M. pneumoniae-associated Stevens-Johnson syndrome","volume":"36","author":"Watkins","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2026061009403905500_ofag333-B68","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00748-21","article-title":"Mycoplasma pneumoniae genotypes and clinical outcome in children","volume":"59","author":"Meyer Sauteur","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2026061009403905500_ofag333-B69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fcimb.2020.00385","article-title":"Periodic genotype shifts in clinically prevalent Mycoplasma pneumoniae strains in Japan","volume":"10","author":"Kenri","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2026061009403905500_ofag333-B70","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1086\/592281","article-title":"Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness","volume":"198","author":"Walter","year":"2008","journal-title":"J Infect Dis"},{"key":"2026061009403905500_ofag333-B71","doi-asserted-by":"crossref","first-page":"E295","DOI":"10.33321\/cdi.2017.41.40","article-title":"Probable epidemic Mycoplasma pneumoniae disease activity in metropolitan Sydney, 2015: combining surveillance data to cross-validate signal detection","volume":"41","author":"Britton","year":"2017","journal-title":"Commun Dis Intell Q Rep"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag333\/68467143\/ofag333.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag333\/68467143\/ofag333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag333\/68467143\/ofag333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:40:52Z","timestamp":1781098852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag333\/8701309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag333","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag333"}}